Retinol dehydrogenase 10 promotes metastasis of glioma cells via the transforming growth factor-b/SMAD signaling pathway
Glioma is the deadliest type of primary brain tumor—accounting for 70% of malignant brain cancers—and its ability to invade healthy tissue and resist chemotherapy/radiotherapy leaves most patients with a median survival of just 12–15 months. For decades, researchers have searched for molecular targets to stop its spread. A 2019 study from Beijing Shijitan and Tiantan Hospitals (affiliated with Capital Medical University) offers new hope: a protein called retinol dehydrogenase 10 (RDH10) plays a key role in glioma metastasis, and blocking it could slow tumor growth.
What Is RDH10—And Why Does It Matter for Glioma?
RDH10 isn’t new to science. Best known for its role in vision (it helps make retinal, the molecule that enables sight) and embryonic development (mice without RDH10 die before birth), it’s a member of the short-chain dehydrogenase/reductase family. But recent research links RDH10 to cancer: it’s overexpressed in liver, prostate, and now glioma cells.
The Beijing team, led by neurosurgeons Feng Guan (Beijing Shijitan Hospital) and Zhuang Kang (Beijing Tiantan Hospital), wanted to answer a critical question: Does RDH10 drive glioma’s most dangerous trait—its ability to spread (metastasize)?
How the Study Worked
The researchers used two common glioma cell lines (U87 and U251) and a technique called lentiviral RNA interference to “silence” RDH10—turning off its production. They then compared these “RDH10-silenced” cells to normal glioma cells (the “control” group) using three key tests:
- Migration (Scratch Assay): A line was drawn in a cell culture, and the team measured how fast cells filled the gap.
- Invasion (Transwell Assay): Cells were placed in a membrane-coated chamber, and the team counted how many moved through to the other side (a proxy for invading healthy tissue).
- Molecular Changes (Western Blotting): The team tested levels of proteins in the TGF-b/SMAD pathway—a known driver of tumor spread.
The Results: RDH10 Fuels Glioma Spread
The study uncovered four critical findings:
1. RDH10 Is Overexpressed in Glioma Cells
Compared to healthy brain cells (normal human astrocytes, or NHA), RDH10 levels were 3–4 times higher in four glioma cell lines (A172, U373, U87, U251). This suggests RDH10 is a “proto-oncogene”—a gene that turns cancerous when overactive.
2. Silencing RDH10 Stops Migration
In the scratch assay, RDH10-silenced cells were far slower to close the gap:
- U87 cells: 2% of the scratch remained unfilled (vs. 1% in controls)—meaning they moved half as fast.
- U251 cells: 2.48% of the scratch remained (vs. 1% in controls)—over two times slower.
3. Silencing RDH10 Stops Invasion
In the transwell assay, RDH10-silenced cells barely invaded through the membrane:
- U87 cells: 13% invaded (vs. 97% of normal cells).
- U251 cells: 18% invaded (vs. 96% of normal cells).
Silencing RDH10 reduced invasion by 85–80%—a dramatic effect.
4. RDH10 Fuels the TGF-b/SMAD Pathway
The biggest breakthrough was uncovering how RDH10 works: it activates the TGF-b/SMAD signaling pathway—a molecular chain that tells cells to grow and spread.
TGF-b (transforming growth factor-beta) is a double-edged sword: in healthy cells, it stops uncontrolled growth. In glioma, it flips roles—promoting invasion, migration, and therapy resistance. The study found:
- Silencing RDH10 reduced TGF-b levels by 47%.
- It cut levels of phosphorylated SMAD2 (a TGF-b target) by 58% and phosphorylated SMAD3 by 59%.
Without these signals, glioma cells lose their ability to migrate or invade.
Why This Matters for Glioma Treatment
This study is a game-changer for three reasons:
- RDH10 Is a New Target: Most glioma therapies focus on killing cells (chemotherapy) or shrinking tumors (radiotherapy). Targeting RDH10 attacks the root of glioma’s deadliness—its ability to spread.
- TGF-b/SMAD Is a Known Pathway: Drugs that block the TGF-b/SMAD pathway are already in trials for other cancers. The study suggests RDH10 inhibitors could work alongside these drugs to hit glioma from two angles.
- Preclinical Promise: While the research was done in cell lines (not humans), the results are strong. The team’s previous work also found RDH10 promotes glioma cell growth—meaning blocking it could slow both growth and spread.
What’s Next?
The study has limitations: it was done in lab-grown cells, not living animals or humans. The next steps are:
- Testing RDH10 inhibitors in mouse models of glioma to see if they slow tumor growth.
- Investigating how RDH10 interacts with other pathways (like NF-kB, which the team linked to glioma proliferation in 2017).
- Exploring whether RDH10 levels in patient tumors correlate with prognosis (a key step for clinical trials).
Conclusion
Glioma’s aggression has frustrated doctors and patients for years, but this study adds a critical piece to the puzzle. By showing that RDH10 drives metastasis via the TGF-b/SMAD pathway, the Beijing team has identified a promising new target for therapy.
For the 50,000+ people diagnosed with glioma annually (per the American Brain Tumor Association), this is a small but crucial step forward. While much work remains, the findings offer hope that one day, we’ll have drugs that don’t just treat glioma—but stop it from spreading.
The study, “Retinol dehydrogenase 10 promotes metastasis of glioma cells via the transforming growth factor-b/SMAD signaling pathway,” was published in the Chinese Medical Journal in 2019 by Feng Guan, Zhuang Kang, and colleagues from Beijing Shijitan and Tiantan Hospitals. The full study is available at doi.org/10.1097/CM9.0000000000000478.
Was this helpful?
0 / 0